ALDEYRA THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
ALDEYRA THERAPEUTICS, INC. (ALDX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 4.32% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-02-27
- ALDEYRA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was 4.32%, a 4.00% decline from fiscal 2023.
- ALDEYRA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 4.50%, a 9.22% increase from fiscal 2022.
- ALDEYRA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was 4.12%, a 3.96% decline from fiscal 2021.
- ALDEYRA THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2021 was 4.29%, a 30.79% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2024-12-31 | 4.32% 10-K · filed 2026-02-27 |
| 2023-12-31 | 4.50% 10-K · filed 2025-02-28 |
| 2022-12-31 | 4.12% 10-K · filed 2024-03-07 |
| 2021-12-31 | 4.29% 10-K · filed 2023-03-09 |
| 2020-12-31 | 3.28% 10-K · filed 2022-03-17 |
| 2019-12-31 | 1.44% 10-K · filed 2021-03-11 |
| 2018-12-31 | 3.81% 10-K · filed 2020-03-12 |
| 2017-12-31 | 3.00% 10-K · filed 2019-03-08 |
| 2016-12-31 | 2.84% 10-K · filed 2018-03-29 |
| 2015-12-31 | 1.92% 10-K · filed 2017-03-30 |
| 2014-12-31 | 3.07% 10-K · filed 2016-03-30 |
| 2013-12-31 | -0.37% 10-K · filed 2015-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |